### Analysis

Merck & Co. reported robust Q2 earnings, despite the challenges posed by the COVID-19 pandemic. The company highlighted strong performance in its key growth areas, including oncology and vaccines. The guidance for 2020 was revised upward, reflecting a more favorable outlook. Management expressed confidence in the company's ability to navigate the pandemic and maintain strong growth. Key concerns include the timing of vaccine approvals and the potential for extended recovery in the vaccine business. Despite these uncertainties, the company's financial strength and operational resilience suggest a positive outlook for the remainder of the year.

### Conclusion

The short-term impact on Merck's stock price is expected to be positive due to the company's strong Q2 performance and revised guidance. The market is likely to react favorably to the company's ability to navigate the pandemic and maintain growth prospects. The stock is expected to rally in the next 1â€“2 weeks.

**Rating: 2**